WCN26-9410 Fanconi Syndrome Induced by Tenofovir Alafenamide in a Patient with Chronic Hepatitis B: A Case Report

Read full text Summarise with VIRAT
Authors: Sihyung Park, Chang Min Heo, Yang Wook Kim, Bong Soo Park
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Tenofovir-related nephrotoxicity is a well-known complication, particularly with tenofovir disoproxil fumarate (TDF). The newer formulation, tenofovir alafenamide (TAF), imposes a much lower burden on the kidneys through a mechanism that achieves high intracellular concentrations while maintaining low plasma tenofovir levels. Nonetheless, few reports have demonstrated that TAF can make kidney problem still.

Fields of Study & Subjects

HIV/AIDS drug development and treatment Renal Diseases and Glomerulopathies Acute Kidney Injury Research

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
103856–103856
Publication date
25 March 2026
Language
EN